ScoreComparison
Why is Fuji Pharma Co., Ltd. ?
1
Weak Long Term Fundamental Strength with a 11.50% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 9.85% and Operating profit at 11.50% over the last 5 years
3
With a growth in Operating Profit of 42.67%, the company declared Very Positive results in Dec 25
- The company has declared positive results in Jan 70 after 2 consecutive negative quarters
- INTEREST COVERAGE RATIO(Q) Highest at 4,511.9
- RAW MATERIAL COST(Y) Fallen by -7.08% (YoY)
- INVENTORY TURNOVER RATIO(HY) Highest at 1.49 times
4
With ROCE of 9.18%, it has a expensive valuation with a 1.12 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 79.77%, its profits have risen by 38.3% ; the PEG ratio of the company is 0.3
5
Market Beating Performance
- The stock has generated a return of 79.77% in the last 1 year, much higher than market (Japan Nikkei 225) returns of 66.43%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Fuji Pharma Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fuji Pharma Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Fuji Pharma Co., Ltd.
-100.0%
1.86
31.27%
Japan Nikkei 225
66.43%
2.61
25.49%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.85%
EBIT Growth (5y)
11.50%
EBIT to Interest (avg)
45.26
Debt to EBITDA (avg)
2.68
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.66
Tax Ratio
20.55%
Dividend Payout Ratio
34.57%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.78%
ROE (avg)
8.24%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.17
EV to EBIT
12.18
EV to EBITDA
7.58
EV to Capital Employed
1.12
EV to Sales
1.46
PEG Ratio
0.27
Dividend Yield
NA
ROCE (Latest)
9.18%
ROE (Latest)
11.59%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
INTEREST COVERAGE RATIO(Q)
Highest at 4,511.9
RAW MATERIAL COST(Y)
Fallen by -7.08% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 1.49 times
NET SALES(Q)
Highest at JPY 15,897 MM
OPERATING PROFIT(Q)
Highest at JPY 3,790 MM
OPERATING PROFIT MARGIN(Q)
Highest at 23.84 %
PRE-TAX PROFIT(Q)
Highest at JPY 2,697 MM
NET PROFIT(Q)
Highest at JPY 2,825 MM
-10What is not working for the Company
INTEREST(HY)
At JPY 177 MM has Grown at 31.11%
ROCE(HY)
Lowest at 4.88%
Here's what is working for Fuji Pharma Co., Ltd.
Interest Coverage Ratio
Highest at 4,511.9
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Pre-Tax Profit
At JPY 2,697 MM has Grown at 127.74%
over average net sales of the previous four periods of JPY 1,184.25 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 2,825 MM has Grown at 212.6%
over average net sales of the previous four periods of JPY 903.71 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Net Sales
Highest at JPY 15,897 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Net Sales
At JPY 15,897 MM has Grown at 23.05%
over average net sales of the previous four periods of JPY 12,919.25 MMMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 3,790 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 23.84 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 2,697 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 2,825 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Inventory Turnover Ratio
Highest at 1.49 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -7.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Fuji Pharma Co., Ltd.
Interest
At JPY 177 MM has Grown at 31.11%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
